Genelux (GNLX) Research Hub

Genelux (GNLX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.91 USD (-4.50%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.36, market cap 0.11B. This hub links to the full technical, earnings and options research available for GNLX.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close1.91 USD (-4.50%)
52-week range1.87 USD – 3.18 USD
Trend regimeRange
14-day RSI25.2 (Oversold)
Trailing P/E-3.36
Market cap0.11B
Dividend yield0.00%
Next earnings2026-08-06

Available research for GNLX

Earnings

GNLX earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -3.36. Updated 2026-07-23.

Options: Covered Call

Covered Call on GNLX: how it works, illustrative setup around the real 1.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on GNLX: how it works, illustrative setup around the real 1.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on GNLX: how it works, illustrative setup around the real 1.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

GNLX technical analysis: range, last 1.91 USD, RSI 25.2, 52w range 1.87 USD–3.18 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is GNLX in?

Genelux (GNLX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is GNLX in an uptrend or downtrend?

As of 2026-10-26, GNLX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is GNLX's trailing P/E ratio?

GNLX's trailing P/E is -3.36, with a market cap of 0.11B. See the earnings research page for full valuation detail.

When does GNLX next report earnings?

GNLX is next scheduled to report earnings on 2026-08-06.